Modeling and Simulation - PK/PD Archives

Publication

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

CertaraAugust 13, 2025

Publication

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…

CertaraAugust 13, 2025

Webinar

Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches

CertaraAugust 1, 2025

Blog

ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered

ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…

CertaraJuly 23, 2025

On-Demand Webinar

Building PK/PD Workflows with Cloud and AI – APAC Webinar

CertaraJuly 15, 2025

Live Events

Phoenix Roadshow 2025 – Copenhagen

CertaraJuly 2, 2025

Blog

The Reference-scaled Average Bioequivalence (RSABE) Approach

We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…

CertaraJuly 1, 2025

Blog

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

June 30, 2025 Drug development is increasingly defined by its complexity. Teams must navigate rising…

CertaraJune 30, 2025

Case Study

How Model-informed drug development rescue projects from a risky situation

Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…

CertaraJune 26, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Modeling and Simulation – PK/PD

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches

ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered

Building PK/PD Workflows with Cloud and AI – APAC Webinar

Phoenix Roadshow 2025 – Copenhagen

The Reference-scaled Average Bioequivalence (RSABE) Approach

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

How Model-informed drug development rescue projects from a risky situation

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Newsletter sign up

Quick links

Solutions

Contact